Residency · Residency · Obstetrics Gynecology

Menopause: Physiology, Diagnosis, and Vasomotor Symptom Management

Introduction

Menopause is defined as the permanent cessation of menstruation resulting from loss of ovarian follicular activity. It is confirmed retrospectively after 12 consecutive months of amenorrhea without another identifiable cause. The average age of natural menopause in the United States is 51 years. The menopausal transition profoundly affects multiple organ systems, and vasomotor symptoms (VMS) are the hallmark complaint, affecting up to 80% of women.

Physiology of the Menopausal Transition

Reproductive Aging

The STRAW+10 staging system (Stages of Reproductive Aging Workshop) divides reproductive life into stages based on menstrual cycle regularity, FSH levels, AMH, and antral follicle count. The early menopausal transition (Stage -2) is characterized by variable cycle length with a persistent difference of 7 or more days from normal, and FSH begins to rise. The late menopausal transition (Stage -1) features intervals of amenorrhea lasting 60 days or more, FSH above 25 IU/L, and marked hormonal fluctuations. Postmenopause (Stage +1 to +2) begins at the final menstrual period, with the early postmenopause lasting 5 to 8 years and featuring continued hormonal changes.

Hormonal Changes

Estradiol decline accelerates in the late transition, with postmenopausal levels typically falling below 20 pg/mL. FSH rises progressively as inhibin B declines and negative feedback is lost, with postmenopausal values exceeding 30 to 40 IU/L. Inhibin B, produced by small antral follicles, declines earlier than estradiol and serves as an early marker of diminishing ovarian reserve. Ovarian testosterone production continues after menopause, meaning the postmenopausal ovary remains hormonally active, while adrenal DHEA-S declines with aging independently of menopause. Estrone becomes the predominant estrogen postmenopausally, produced by aromatization of androstenedione in adipose tissue.

<image>Graph illustrating hormonal changes across the menopausal transition according to STRAW+10 staging, showing declining estradiol and inhibin B levels with rising FSH levels from the reproductive years through late postmenopause, with labeled transition stages</image>

Diagnosis

Menopause is a clinical diagnosis in women of appropriate age, typically over 45, who have experienced 12 months of amenorrhea without other cause. No laboratory testing is needed in most cases. Testing with FSH and estradiol is appropriate in women aged 40 to 45 with menopausal symptoms or amenorrhea, in women under 40 to evaluate for premature ovarian insufficiency, and in women who have had a hysterectomy without oophorectomy. An FSH above 30 IU/L on two measurements taken 4 to 6 weeks apart in the setting of amenorrhea confirms menopause. AMH is the most reliable biochemical marker of ovarian reserve, and undetectable AMH precedes the final menstrual period by approximately 5 years. The differential diagnosis of amenorrhea includes pregnancy, thyroid disease, hyperprolactinemia, hypothalamic amenorrhea, and Asherman syndrome.

Vasomotor Symptoms

Clinical Features

Hot flashes and night sweats affect 75 to 80% of menopausal women. The median duration is 7.4 years, and symptoms may persist for more than 10 years in some women. The SWAN study found that the median VMS duration was longer for Black women (10.1 years) and shorter for Japanese and Chinese women (4.8 to 5.4 years). The pathophysiology involves narrowing of the thermoneutral zone in the hypothalamus, mediated by kisspeptin/neurokinin B/dynorphin (KNDy) neurons in the arcuate nucleus. Declining estrogen reduces the thermoneutral zone, triggering heat dissipation responses at smaller core temperature elevations. The impact includes sleep disruption, impaired concentration, reduced quality of life, workplace productivity loss, and correlation with increased cardiovascular risk markers.

Hormone Therapy for VMS

Hormone therapy is the most effective treatment, reducing VMS frequency by 75 to 90%. Systemic estrogen options include oral formulations such as conjugated equine estrogens (CEE) at 0.3 to 0.625 mg or micronized estradiol at 0.5 to 1 mg. Transdermal estradiol patches at 0.025 to 0.05 mg are the preferred route for women with hypertriglyceridemia, migraine, VTE risk factors, or gallbladder disease. Topical options include estradiol gel and spray. Progestogen is required for endometrial protection in women with an intact uterus to prevent endometrial hyperplasia and cancer. Continuous options include medroxyprogesterone acetate (MPA) 2.5 mg daily or micronized progesterone 100 mg daily. Cyclic options include MPA 5 to 10 mg or micronized progesterone 200 mg for 12 to 14 days per month. The levonorgestrel IUD (52 mg) provides both endometrial protection and contraception during the transition. The tissue-selective estrogen complex, conjugated estrogens 0.45 mg combined with bazedoxifene 20 mg (Duavee), uses a SERM component to provide endometrial protection without progestogen.

Timing and Duration

The timing hypothesis holds that initiation of hormone therapy within 10 years of menopause or before age 60 is associated with cardiovascular benefit, whereas initiation after this window may increase cardiovascular risk. The WHI findings in proper context showed that CEE plus MPA in women aged 50 to 59 demonstrated no increase in coronary heart disease, and CEE alone in hysterectomized women aged 50 to 59 showed reduced CHD and breast cancer risk. Regarding duration, the lowest effective dose should be used for the shortest duration consistent with treatment goals, though no mandatory time limit exists. The decision should be individualized based on ongoing symptom burden and risk assessment. Discontinuation should be gradual to minimize symptom recurrence, as approximately 50% of women will have recurrent VMS upon stopping hormone therapy.

<image>Decision algorithm for vasomotor symptom management showing initial assessment of symptom severity, risk stratification for hormone therapy (including age, years since menopause, VTE history, breast cancer history, cardiovascular risk), and treatment pathways leading to HT, non-hormonal options, or lifestyle modifications</image>

Non-Hormonal Pharmacologic Options

Fezolinetant (Veozah) is an NK3 receptor antagonist targeting KNDy neurons that was FDA-approved in 2023. It reduces VMS by 60 to 65%. Hepatic function must be monitored, and it is contraindicated with CYP1A2 inhibitors. SSRIs and SNRIs are also effective: paroxetine 7.5 mg (Brisdelle) is the only FDA-approved SSRI for VMS; escitalopram 10 to 20 mg, venlafaxine 75 to 150 mg, and desvenlafaxine 100 to 150 mg reduce VMS by 40 to 65%. Gabapentin at 300 to 900 mg at bedtime is particularly useful when sleep disruption is prominent. Clonidine 0.1 mg orally or transdermally has modest efficacy but is limited by hypotension and sedation. Oxybutynin 2.5 to 5 mg twice daily or as extended-release has recent evidence showing 70 to 80% VMS reduction.

Lifestyle and Complementary Approaches

Behavioral approaches with evidence include cognitive behavioral therapy for hot flashes (CBT-Meno) and clinical hypnosis, both of which achieve 40 to 75% symptom improvement. Lifestyle measures include weight loss in overweight women (which reduces VMS), layered clothing, cool environments, and avoidance of triggers such as alcohol, spicy foods, and caffeine. Black cohosh, soy isoflavones, evening primrose oil, and acupuncture have limited or inconsistent evidence and are not recommended as primary treatment.

Clinical Pearls

Menopause is a clinical diagnosis in women over 45. FSH testing is unnecessary in the typical clinical presentation.

Hormone therapy remains the gold standard for moderate-to-severe VMS. The benefits outweigh the risks for symptomatic women within 10 years of menopause or under age 60.

Transdermal estrogen is preferred for women with elevated VTE risk, hypertriglyceridemia, or migraine, as it avoids first-pass hepatic effects.

Fezolinetant represents the first mechanism-based non-hormonal therapy for VMS, targeting the KNDy neuron pathway.

Progestogen is mandatory for endometrial protection when systemic estrogen is given to women with an intact uterus. The levonorgestrel IUD is an acceptable alternative.

References

1. The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
2. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539.
3. Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms: SKYLIGHT 1 and 2 randomized clinical trials. J Clin Endocrinol Metab. 2023;108(8):1981-1997.
4. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938.

Read this lecture as Markdown